Cerecor picks up a Lilly antidepressant with ambitions in addiction

Damian Garde Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders.  FierceBiotech News

Lilly extends study of highly anticipated cholesterol fighter

Eric Palmer Eli Lilly says it will extend the massive Phase III trial for its highly anticipated drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," ...

Struggling Lilly, AbbVie may find Low-T boost from specialized testosterone clinics

Carly Helfand After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their ...

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing ...

Lilly says with new data, it will seek another approval for Cyramza next year

Eric Palmer Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to ...

Lilly, Boehringer win FDA approval for once-rejected diabetes drug

Damian Garde After a manufacturing issue scuttled their first attempt, Eli Lilly and Boehringer Ingelheim have won the FDA's blessing to market their new diabetes drug, a late entrant ...

Sanofi hits Lilly with more Lantus infringement charges

Carly Helfand Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until ...

Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

Eric Palmer Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning ...

Eli Lilly gets on the trial transparency bandwagon

Damian Garde In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all. FierceBiotech ...

Lilly buys back a migraine therapy from Arteaus Therapeutics

Emily Mullin Eli Lilly has struck a deal with Arteaus Therapeutics to acquire the Cambridge, MA-based company's migraine therapy being studied in a Phase II clinical trial. FierceBiotech ...

Eli Lilly spells out $1.8B deal to partner with Pfizer on tanezumab

John Carroll When Pfizer first let slip that it struck a deal to collaborate with Eli Lilly on the high-risk anti-NGF pain drug tanezumab, the news was delivered without any of the ...

Eli Lilly CEO still believes in that $5B budget for R&D

Tracy Staton Lechleiter tells The Wall Street Journalthat he sees "the light at the end of the tunnel," but if pipeline failures continue, then cuts would have to follow. FiercePharma ...
Page 2 of 612345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS